Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
Publication
, Journal Article
Nordness, MF; Hamel, S; Godfrey, CM; Shi, C; Johnson, DB; Goff, LW; O'Dell, H; Perri, RE; Alexopoulos, SP
Published in: Am J Transplant
March 2020
Nivolumab is an immune checkpoint inhibitor (ICI) currently in phase 3 clinical trials for hepatocellular carcinoma. The safety of ICIs in recipients of organ allotransplant is unclear, and several reports of fatal alloimmune injury after posttransplant ICI use have been published. We present the first published case of nivolumab used in the pretransplant setting for HCC resulting in fatal acute hepatic necrosis in the immediate postoperative period from a profound immune reaction likely propagated by nivolumab. Further investigation and significant caution are needed in the evaluation of patients awaiting transplant who are receiving ICI therapy.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am J Transplant
DOI
EISSN
1600-6143
Publication Date
March 2020
Volume
20
Issue
3
Start / End Page
879 / 883
Location
United States
Related Subject Headings
- Surgery
- Programmed Cell Death 1 Receptor
- Nivolumab
- Necrosis
- Liver Transplantation
- Liver Neoplasms
- Humans
- Carcinoma, Hepatocellular
- Antibodies, Monoclonal
- 3204 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Nordness, M. F., Hamel, S., Godfrey, C. M., Shi, C., Johnson, D. B., Goff, L. W., … Alexopoulos, S. P. (2020). Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant, 20(3), 879–883. https://doi.org/10.1111/ajt.15617
Nordness, Mina F., Stephanie Hamel, Caroline M. Godfrey, Chanjuan Shi, Douglas B. Johnson, Laura W. Goff, Heather O’Dell, Roman E. Perri, and Sophoclis P. Alexopoulos. “Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?” Am J Transplant 20, no. 3 (March 2020): 879–83. https://doi.org/10.1111/ajt.15617.
Nordness MF, Hamel S, Godfrey CM, Shi C, Johnson DB, Goff LW, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant. 2020 Mar;20(3):879–83.
Nordness, Mina F., et al. “Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?” Am J Transplant, vol. 20, no. 3, Mar. 2020, pp. 879–83. Pubmed, doi:10.1111/ajt.15617.
Nordness MF, Hamel S, Godfrey CM, Shi C, Johnson DB, Goff LW, O’Dell H, Perri RE, Alexopoulos SP. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant. 2020 Mar;20(3):879–883.
Published In
Am J Transplant
DOI
EISSN
1600-6143
Publication Date
March 2020
Volume
20
Issue
3
Start / End Page
879 / 883
Location
United States
Related Subject Headings
- Surgery
- Programmed Cell Death 1 Receptor
- Nivolumab
- Necrosis
- Liver Transplantation
- Liver Neoplasms
- Humans
- Carcinoma, Hepatocellular
- Antibodies, Monoclonal
- 3204 Immunology